# Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

> **NCT04819399** · PHASE1 · UNKNOWN · sponsor: **Lindis Biotech GmbH** · enrollment: 30 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** Catumaxomab

## Key facts

- **NCT ID:** NCT04819399
- **Lead sponsor:** Lindis Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-07
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04819399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04819399, "Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04819399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*